Clinical Trials Logo

Lymphoma clinical trials

View clinical trials related to Lymphoma.

Filter by:

NCT ID: NCT01142674 Completed - Clinical trials for Lymphoma, T-Cell, Peripheral

T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma

Start date: September 2006
Phase:
Study type: Observational

The designed study follows up the retrospective previous one by the International T-cell Non-Hodgkin's Lymphoma Study Group (International Peripheral T-Cell Lymphoma Project). It is designed as a prospective collection of information potentially useful to predict the prognosis of newly diagnosed patients with the more frequent subtypes of Peripheral T-cell lymphoma (Peripheral T-cell lymphoma unspecified and Angioimmunoblastic T-cell lymphoma) and to better define clinical characteristics and outcome of the more uncommon subtypes

NCT ID: NCT01141712 Completed - Lymphoma Clinical Trials

Autologous Transplant in HIV Patients (BMT CTN 0803)

Start date: April 2010
Phase: Phase 2
Study type: Interventional

This study is a Phase II, multicenter trial assessing overall survival after autologous hematopoietic stem cell transplantation using a BEAM transplant regimen (carmustine, etoposide, cytarabine, melphalan) in lymphoma patients with HIV.

NCT ID: NCT01139359 Withdrawn - Lymphoma Clinical Trials

Safety Study of Darinaparsin in Combination With Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) to Treat Lymphoma

Start date: June 2010
Phase: Phase 1
Study type: Interventional

This study is a Phase I trial of Darinaparsin in combination with CHOP for the treatment of lymphoma. Eligible patients will not have had any previous anti-cancer treatment and will be eligible to receive CHOP alone.

NCT ID: NCT01138579 Withdrawn - Leukemia Clinical Trials

Study of the Trifunctional Antibody FBTA05 and Donor Lymphocyte Infusion in B-cell Lymphoma After Allogeneic Stem Cell Transplantation

STP-LYM-01
Start date: August 2010
Phase: Phase 1/Phase 2
Study type: Interventional

This study is an investigator driven, open-label, non-randomized, uncontrolled, dose escalating Phase I/II study evaluating the safety and preliminary efficacy of the trifunctional bispecific antibody FBTA05 in combination with donor lymphocyte infusions (DLI) for treatment of relapsed or refractory disease in CD20 positive either low- or high-grade non-Hodgkin´s lymphoma after allogeneic transplantation

NCT ID: NCT01137825 Recruiting - Lymphoma Clinical Trials

Registry of Older Patients With Cancer

Start date: September 2009
Phase:
Study type: Observational

RATIONALE: Gathering information about older patients with cancer may help the study of cancer in the future. PURPOSE: This research study is gathering information from older patients with cancer into a registry.

NCT ID: NCT01137643 Recruiting - Lymphoma Clinical Trials

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

Start date: July 2009
Phase:
Study type: Observational

RATIONALE: Collecting and storing samples of tissue, blood, and body fluid from patients with cancer to study in the laboratory may help the study of cancer in the future. PURPOSE: This research study is collecting and storing blood and tissue samples from patients being evaluated for hematologic cancer.

NCT ID: NCT01135329 Terminated - Lymphoma Clinical Trials

Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers

Start date: August 2010
Phase: Phase 2
Study type: Interventional

This research is being done to learn more about reduced-intensity bone marrow transplantation (BMT), also known as a "mini" transplant for patients with blood cancers, using bone marrow from a relative. The main goal of the study is to determine how quickly the donor's bone marrow "takes" in your body. Other goals include describing how many people accept the bone marrow and how quickly the blood counts come up; describing Graft-versus-host disease (GVHD) and other complications; and describing how many people survive without progressive cancer and survive overall

NCT ID: NCT01134341 Completed - Mycosis Fungoides Clinical Trials

Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma

Start date: March 2010
Phase: Phase 1
Study type: Interventional

This study is designed to determine the recommended dose, safety, pharmacokinetics, and early efficacy of the combination of pralatrexate plus oral bexarotene in patients with relapsed or refractory CTCL.

NCT ID: NCT01133158 Completed - Clinical trials for Non-Hodgkin's Lymphoma

R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial

Start date: July 2009
Phase: Phase 2
Study type: Interventional

Assess the combination of efficacy of the combination of rituximab, bendamustine, mitoxantrone, dexamethasone in the treatment of patients with Follicular Lymphoma.

NCT ID: NCT01132989 Recruiting - Clinical trials for Cutaneous T Cell Lymphoma

Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma

REvMM2009
Start date: May 2010
Phase: Phase 2
Study type: Interventional

Patients with cutaneous T cell lymphoma experience refractory and progressive disease despite current treatment, necessitating chronic disease management. In addition, there needs to be greater emphasis on combination treatment, which correlates with increased response rate, more rapid onset of response, and decreased side effect profile compared to monotherapy. The goal for the use of Lenalidomide as an adjuvant treatment in patients with refractory cutaneous T cell lymphoma is to increase response rates, maintain a durable long-term response, relieve associated symptoms, and minimize toxic side effects.